Minocycline protects against delayed cerebral ischemia after subarachnoid hemorrhage via matrix metalloproteinase-9 inhibition.
Ananth K VellimanaMeng-Liang ZhouItender SinghDiane J AumJames W NelsonGlenn R HarrisUmeshkumar AthiramanByung H HanGregory J ZipfelPublished in: Annals of clinical and translational neurology (2017)
MMP-9 is a key player in the pathogenesis of DCI. The consistent attenuation of multiple components of DCI with both pre- and post-SAH administration of minocycline across different species and experimental models of SAH, combined with the excellent safety profile of minocycline in humans suggest that a clinical trial in SAH patients is warranted.